Fig. 2
From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
Change from baseline in ACQ-5 score at Week 24 by comorbidity category. Change from baseline in ACQ-5 score was analyzed using a MMRM analysis. The currently accepted minimum clinically important difference for ACQ-5 score is 0.5 points (established in adults with symptomatic asthma) [38]. p-interaction < 0.1. ACQ, Asthma Control Questionnaire; AR allergic rhinitis/hay fever; CI confidence interval; GERD gastroesophageal reflux disease; mepo mepolizumab; MMRM mixed model repeated measures